TOVX
Income statement / Annual
Last year (2024), Theriva Biologics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Theriva Biologics, Inc.'s net income was -$25.65 M.
See Theriva Biologics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$135,000.00
|
$268,000.00
|
$87,000.00
|
$201,000.00
|
$240,000.00
|
$272,000.00
|
$245,000.00
|
$157,000.00
|
$72,000.00
|
| Gross Profit |
$0.00
|
-$135,000.00
|
-$268,000.00
|
-$87,000.00
|
-$201,000.00
|
-$240,000.00
|
-$272,000.00
|
-$245,000.00
|
-$157,000.00
|
-$72,000.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$12.03 M
|
$14.31 M
|
$11.72 M
|
$7.80 M
|
$5.13 M
|
$11.08 M
|
$11.84 M
|
$18.78 M
|
$29.11 M
|
$32.91 M
|
| General & Administrative Expenses |
$7.40 M
|
$7.16 M
|
$9.86 M
|
$6.47 M
|
$5.03 M
|
$4.58 M
|
$5.73 M
|
$7.47 M
|
$10.14 M
|
$8.07 M
|
| Selling & Marketing Expenses |
$0.00
|
$624,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$7.40 M
|
$7.78 M
|
$9.86 M
|
$6.47 M
|
$5.03 M
|
$4.58 M
|
$5.73 M
|
$7.47 M
|
$10.14 M
|
$8.07 M
|
| Other Expenses |
$0.00
|
-$660,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$19.43 M
|
$21.43 M
|
$21.58 M
|
$14.27 M
|
$10.16 M
|
$15.66 M
|
$17.57 M
|
$26.25 M
|
$39.25 M
|
$40.98 M
|
| Cost And Expenses |
$26.35 M
|
$21.43 M
|
$21.58 M
|
$14.27 M
|
$10.16 M
|
$15.66 M
|
$17.57 M
|
$26.25 M
|
$39.25 M
|
$40.98 M
|
| Interest Income |
$697,000.00
|
$1.44 M
|
$512,000.00
|
$6,000.00
|
$44,000.00
|
$283,000.00
|
$67,000.00
|
$21,000.00
|
$37,000.00
|
$6,000.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
$135,000.00
|
$268,000.00
|
$87,000.00
|
$201,000.00
|
$240,000.00
|
$272,000.00
|
$245,000.00
|
$157,000.00
|
$72,000.00
|
| EBITDA |
-$25.52 M |
-$19.85 M |
-$21.58 M |
-$14.19 M |
-$9.96 M |
-$15.42 M |
-$17.30 M |
-$26.01 M |
-$39.10 M |
-$40.91 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$693,000.00
|
$1.44 M
|
$471,000.00
|
$6,000.00
|
$44,000.00
|
$283,000.00
|
$4.15 M
|
$10.76 M
|
$11.45 M
|
-$3.81 M
|
| Income Before Tax |
-$25.65 M
|
-$19.99 M
|
-$21.11 M
|
-$14.27 M
|
-$10.12 M
|
-$15.38 M
|
-$13.42 M
|
-$15.49 M
|
-$27.80 M
|
-$44.79 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
-$1.64 M
|
-$1.43 M
|
-$94,000.00
|
-$117,000.00
|
-$360,000.00
|
-$4.20 M
|
-$11.08 M
|
-$12.00 M
|
$2.76 M
|
| Net Income |
-$25.65 M
|
-$18.35 M
|
-$19.69 M
|
-$14.17 M
|
-$10.00 M
|
-$15.02 M
|
-$13.37 M
|
-$15.17 M
|
-$27.26 M
|
-$43.74 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-19.03 |
-28.49 |
-32.11 |
-1.16 |
-5.26 |
-9.14 |
-21.45 |
-42.7 |
-101.17 |
-189.68 |
| EPS Diluted |
-19.03 |
-28.48 |
-32.11 |
-1.16 |
-5.26 |
-9.14 |
-21.45 |
-42.7 |
-101.17 |
-189.68 |
| Weighted Average Shares Out |
$1.35 M
|
$644,000.00
|
$613,090.00
|
$12.19 M
|
$1.90 M
|
$1.64 M
|
$623,244.00
|
$355,331.00
|
$269,397.00
|
$230,584.00
|
| Weighted Average Shares Out Diluted |
$1.35 M
|
$644,280.00
|
$613,090.00
|
$12.19 M
|
$1.90 M
|
$1.64 M
|
$623,244.00
|
$355,331.00
|
$269,397.00
|
$230,584.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
